Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
3.040
+0.190 (6.67%)
Jan 22, 2026, 2:13 PM EST - Market open
Serina Therapeutics Revenue
Serina Therapeutics had revenue of $116.00K in the twelve months ending September 30, 2025, down -96.33% year-over-year. In the year 2024, Serina Therapeutics had annual revenue of $56.00K, down -98.22%.
Revenue (ttm)
$116.00K
Revenue Growth
-96.33%
P/S Ratio
240.85
Revenue / Employee
$8,923
Employees
13
Market Cap
32.42M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 56.00K | -3.10M | -98.22% |
| Dec 31, 2023 | 3.15M | 3.12M | 9,173.53% |
| Dec 31, 2022 | 34.00K | -110.00K | -76.39% |
| Dec 31, 2021 | 144.00K | -217.00K | -60.11% |
| Dec 31, 2020 | 361.00K | -1.37M | -79.11% |
| Dec 31, 2019 | 1.73M | 332.00K | 23.78% |
| Dec 31, 2018 | 1.40M | -8.00K | -0.57% |
| Dec 31, 2017 | 1.40M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cue Biopharma | 7.10M |
| Marker Therapeutics | 4.69M |
| Dyadic International | 3.34M |
| Outlook Therapeutics | 1.41M |
| Pluri | 1.33M |
SER News
- 6 days ago - Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity - GlobeNewsWire
- 5 weeks ago - Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry - GlobeNewsWire
- 6 weeks ago - Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program - GlobeNewsWire
- 2 months ago - Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewsWire
- 2 months ago - Serina Therapeutics Provides Regulatory Update on SER-252 Program - GlobeNewsWire
- 3 months ago - Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors - GlobeNewsWire
- 3 months ago - Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease - GlobeNewsWire
- 4 months ago - Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease - GlobeNewsWire